Skip to main content
Clinical Trials/DRKS00014825
DRKS00014825CompletedNot Applicable

Multicentre Non-interventional Study of Treatment Outcome in Heart Failure Patients with Hyperkalaemia under RAASi-treatment Receiving Veltassa in Routine Practice - CONTINUE-HF NIS

Vifor Pharma Deutschland GmbH0 sites22 target enrollmentStarted: June 7, 2018Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
22

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational

Eligibility Criteria

Ages
18 Years to one (—)
Sex
All

Inclusion Criteria

  • 1. 18 years or older
  • 2. signed informed consent
  • 3. heart failure with left ventricular ejection fraction less than 40%
  • 4. with or without chronic renal insufficiency
  • 5. therapy with inhibitors of the renin-angiotensin-aldosterone-system (RAASi)
  • 6. hyperkalemia (serum potassium values equal/higher than 5.1 mmol/L at baseline that limits ability to maintain or increase the dose of RAASi
  • 7. scheduled for treatment with Veltassa as per label

Exclusion Criteria

  • 1. current dialysis or anticipated during study participation
  • 2. type I diabetes mellitus
  • 3. acute kidney injury
  • 4. cancer with less than 12 months life expectancy
  • 5. heart or kidney transplantation or anticipated during study participation
  • 6. investigational medication currently, 21 days or 5 half-lives prior to baseline
  • 7. inability to consume Veltassa
  • 8. severe medical condition currently or in the last 21 days prior baseline which could decrease study compliance or jeopardize the safety of the patient.

Investigators

Similar Trials